ECSP19021312A - Formulaciones de anticuerpos inhibidores de masp-2 altamente concentrados, de baja viscosidad, kits, y métodos - Google Patents

Formulaciones de anticuerpos inhibidores de masp-2 altamente concentrados, de baja viscosidad, kits, y métodos

Info

Publication number
ECSP19021312A
ECSP19021312A ECSENADI201921312A ECDI201921312A ECSP19021312A EC SP19021312 A ECSP19021312 A EC SP19021312A EC SENADI201921312 A ECSENADI201921312 A EC SENADI201921312A EC DI201921312 A ECDI201921312 A EC DI201921312A EC SP19021312 A ECSP19021312 A EC SP19021312A
Authority
EC
Ecuador
Prior art keywords
kits
masp
low viscosity
methods
highly concentrated
Prior art date
Application number
ECSENADI201921312A
Other languages
English (en)
Inventor
Kenneth Ferguson
John Whitaker
Gregory A Demopulos
William Lambert
Original Assignee
Omeros Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omeros Corp filed Critical Omeros Corp
Publication of ECSP19021312A publication Critical patent/ECSP19021312A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a formulaciones de anticuerpos inhibidores de MASP-2 estables, de alta concentración y de baja viscosidad, a kits que comprenden las formulaciones y a métodos terapéuticos que usan las formulaciones y a kits para inhibir los efectos adversos de la activación del complemento dependiente de MASP-2.
ECSENADI201921312A 2016-08-31 2019-03-27 Formulaciones de anticuerpos inhibidores de masp-2 altamente concentrados, de baja viscosidad, kits, y métodos ECSP19021312A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662382156P 2016-08-31 2016-08-31

Publications (1)

Publication Number Publication Date
ECSP19021312A true ECSP19021312A (es) 2019-04-30

Family

ID=61301617

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI201921312A ECSP19021312A (es) 2016-08-31 2019-03-27 Formulaciones de anticuerpos inhibidores de masp-2 altamente concentrados, de baja viscosidad, kits, y métodos

Country Status (40)

Country Link
US (2) US11628217B2 (es)
EP (2) EP4438060A3 (es)
JP (2) JP6864747B2 (es)
KR (2) KR20190043161A (es)
CN (3) CN116327695A (es)
AR (1) AR109494A1 (es)
AU (2) AU2017321605B2 (es)
CA (1) CA3035252C (es)
CL (1) CL2019000508A1 (es)
CO (1) CO2019002239A2 (es)
CR (1) CR20190150A (es)
CU (1) CU20190015A7 (es)
DK (1) DK3506886T3 (es)
EA (1) EA201990598A1 (es)
EC (1) ECSP19021312A (es)
ES (1) ES2986902T3 (es)
FI (1) FI3506886T3 (es)
GE (1) GEP20217252B (es)
HR (1) HRP20241131T1 (es)
HU (1) HUE068084T2 (es)
IL (1) IL265071B2 (es)
JO (1) JOP20170170B1 (es)
LT (1) LT3506886T (es)
MA (1) MA46109A (es)
MX (2) MX2019002338A (es)
MY (1) MY189411A (es)
PE (1) PE20190469A1 (es)
PH (1) PH12019500365A1 (es)
PL (1) PL3506886T3 (es)
PT (1) PT3506886T (es)
PY (1) PY1763675A (es)
RS (1) RS65845B1 (es)
SG (2) SG11201901444PA (es)
SI (1) SI3506886T1 (es)
SM (1) SMT202400333T1 (es)
TW (2) TWI719245B (es)
UA (1) UA122733C2 (es)
UY (1) UY37391A (es)
WO (1) WO2018045054A1 (es)
ZA (1) ZA201901891B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102528260B1 (ko) * 2016-01-05 2023-05-04 유니버시티 오브 레스터 필요로 하는 대상체에서 섬유증의 억제 방법
JOP20170170B1 (ar) * 2016-08-31 2022-09-15 Omeros Corp صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
EP3525798A4 (en) * 2016-10-13 2020-07-08 University Of Leicester METHODS OF REDUCING PROTEINURY IN A HUMAN SUBJECT SUFFERING FROM IMMUNOGLOBULIN A NEPHROPATHY
KR20200037863A (ko) * 2017-08-25 2020-04-09 오메로스 코포레이션 고도로 농축된 저점도 masp-2 억제 항체 제제, 키트, 및 비정형 용혈성 증후군을 앓고 있는 대상체의 치료 방법
US20230182041A1 (en) * 2018-04-25 2023-06-15 Medimmune, Llc Purification of antibodies
IL311042B1 (en) 2018-05-29 2026-04-01 Omeros Corp MASP-2 inhibitors and methods of use
WO2020016417A1 (en) 2018-07-19 2020-01-23 Ichnos Sciences S.A. Liquid antibody formulation
CN120241997A (zh) 2019-02-18 2025-07-04 伊莱利利公司 治疗性抗体制剂
US20220273796A1 (en) * 2019-07-19 2022-09-01 Ichnos Sciences SA Lyophilized antibody formulation
MX2022006334A (es) * 2019-11-26 2022-06-22 Omeros Corp Metodos para tratar y/o prevenir el sindrome de neumonia idiopatica (ips) y/o el sindrome de fuga capilar (cls) y/o el sindrome de injerto (es) y/o la sobrecarga de fluidos (fo) asociados con el trasplante de celulas madre hematopoyeticas.
BR112022010895A2 (pt) 2019-12-04 2022-09-06 Omeros Corp Composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio associado à serina protease-2 associada à lectina de ligação ao manan
IL293588B1 (en) 2019-12-04 2026-04-01 Omeros Corp 3-Amino-1-methylpyrazin-2(H1)-one derivatives as MASP-2 inhibitors, compositions containing them and uses thereof
EP4069676A1 (en) 2019-12-04 2022-10-12 Omeros Corporation Masp-2 inhibitors and methods of use
EP4069678A1 (en) 2019-12-04 2022-10-12 Omeros Corporation Masp-2 inhibitors and methods of use
JP2023537316A (ja) 2020-07-31 2023-08-31 アラマブ セラピューティクス， インコーポレイテッド 抗コネキシン抗体製剤
JP2023547621A (ja) * 2020-10-22 2023-11-13 アラコス インコーポレイテッド 抗ｓｉｇｌｅｃ－８抗体製剤
CA3221859A1 (en) * 2021-06-08 2022-12-15 Xiaowu Liu Anti-masp-2 antibody and use thereof
US20230265215A1 (en) 2021-12-10 2023-08-24 Omeros Corporation Therapeutic antibodies that bind to the serine protease domain of masp-2 and uses thereof
WO2023173036A2 (en) * 2022-03-10 2023-09-14 Omeros Corporation Masp-2 and masp-3 inhibitors, and related compositions and methods, for treatment of sickle cell disease
EP4626891A1 (en) 2022-11-30 2025-10-08 Omeros Corporation Fused pyrimidines as masp-2 inhibitors
EP4643878A2 (en) * 2022-12-29 2025-11-05 Suzhou Transcenta Therapeutics Co., Ltd. Pharmaceutical preparation comprising therapeutic antibody and use thereof
WO2024226573A2 (en) * 2023-04-25 2024-10-31 Nuvance Health Masp-2 directed cancer treatment methods
US12216123B2 (en) 2023-04-25 2025-02-04 Nuvance Health Extracellular vesicle derived MASP-2 directed cancer treatment methods
CN116712390B (zh) * 2023-08-04 2023-11-14 上海览屹医药科技有限公司 一种高浓度高稳定性的抗体制剂及其制备方法
US12427185B2 (en) 2023-09-05 2025-09-30 E-Star Biotech, LLC Formulations of MANP and uses thereof
US20250122225A1 (en) 2023-10-06 2025-04-17 Omeros Corporation Masp-2 inhibitors and methods of use
CN121490076A (zh) * 2026-01-13 2026-02-10 上海麦济医药有限公司 一种稳定的抗人masp2单克隆抗体制剂

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
BRPI0620316A2 (pt) 2005-12-21 2011-11-08 Wyeth Corp formulações de proteìnas com viscosidades reduzida e seus usos
DK2488203T3 (en) 2009-10-16 2017-03-13 Omeros Corp METHODS OF TREATING DISSEMINATED INTRAVASCULAR COAGULATION BY INHIBITION OF MASP-2 DEPENDENT COMPLEMENT ACTIVATION
US9072668B2 (en) * 2010-03-09 2015-07-07 Janssen Biotech, Inc. Non-aqueous high concentration reduced viscosity suspension formulations of antibodies
US9644035B2 (en) 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US20150166676A1 (en) * 2011-04-08 2015-06-18 Omeros Corporation Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
BR112013025917A2 (pt) * 2011-04-08 2016-12-20 Omeros Corp uso de um anticorpo masp-2 ou fragmento do mesmo que inibe ativação de complemento dependente de masp-2
MX367097B (es) * 2011-05-02 2019-08-05 Millennium Pharm Inc FORMULACION PARA ANTICUERPO ANTI-A4ß7.
HUE049154T2 (hu) * 2011-05-04 2020-09-28 Omeros Corp Készítmények a MASP-2-függõ komplement-aktiválás gátlására
BR112014031522A2 (pt) * 2012-06-18 2017-08-01 Omeros Corp métodos para inibir a ativação de complemento dependente de masp-3, para inibir a ativação de complemento dependente de masp-2 e para fabricar um medicamento
WO2014141149A1 (en) 2013-03-15 2014-09-18 Glaxosmithkline Intellectual Property (No.2) Limited Formulations with reduced viscosity
JP2016539919A (ja) * 2013-10-17 2016-12-22 オメロス コーポレーション Ｍａｓｐ−２依存性補体活性化に関連した状態を治療するための方法
CA2959571A1 (en) * 2014-09-03 2016-03-10 Medimmune Limited Stable anti-il-4r-alpha antibody formulation
WO2016109822A1 (en) 2014-12-31 2016-07-07 Novelmed Therapeutics, Inc. Formulation of aglycosylated therapeutic antibodies
AU2016354117B2 (en) 2015-11-09 2019-11-28 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US20170253667A1 (en) 2016-01-05 2017-09-07 University Of Leicester Methods for inhibiting fibrosis in a subject in need thereof
KR102528260B1 (ko) 2016-01-05 2023-05-04 유니버시티 오브 레스터 필요로 하는 대상체에서 섬유증의 억제 방법
MX2018011648A (es) 2016-03-31 2019-01-30 Omeros Corp Metodos para la inhibicion de fibrosis en un sujeto en necesidad del mismo.
JOP20170170B1 (ar) * 2016-08-31 2022-09-15 Omeros Corp صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
TWI834025B (zh) * 2020-03-06 2024-03-01 美商奥默羅斯公司 用於治療和/或預防冠狀病毒誘導的急性呼吸窘迫症候群的抑制masp-2的方法

Also Published As

Publication number Publication date
EP4438060A3 (en) 2024-12-25
IL265071B2 (en) 2023-12-01
CN116327695A (zh) 2023-06-27
US20230226178A1 (en) 2023-07-20
US20180153988A1 (en) 2018-06-07
RS65845B1 (sr) 2024-09-30
IL265071B1 (en) 2023-08-01
EA201990598A1 (ru) 2019-07-31
WO2018045054A1 (en) 2018-03-08
CR20190150A (es) 2019-05-14
AU2017321605A1 (en) 2019-02-07
US11628217B2 (en) 2023-04-18
IL265071A (es) 2019-04-30
ES2986902T3 (es) 2024-11-13
TWI730310B (zh) 2021-06-11
CN109890367B (zh) 2022-08-30
DK3506886T3 (da) 2024-08-19
EP3506886A4 (en) 2019-10-09
HRP20241131T1 (hr) 2024-11-22
TW201944983A (zh) 2019-12-01
ZA201901891B (en) 2019-12-18
AU2020277135A1 (en) 2020-12-24
MX2023014120A (es) 2023-12-12
EP3506886B1 (en) 2024-05-22
EP4438060A2 (en) 2024-10-02
AU2020277135B2 (en) 2023-11-02
CO2019002239A2 (es) 2019-03-18
TW201811365A (zh) 2018-04-01
KR20190043161A (ko) 2019-04-25
CN109890367A (zh) 2019-06-14
CU20190015A7 (es) 2019-11-04
MY189411A (en) 2022-02-10
SG11201901444PA (en) 2019-03-28
SI3506886T1 (sl) 2024-09-30
CA3035252C (en) 2021-08-10
GEP20217252B (en) 2021-05-13
JP7197623B2 (ja) 2022-12-27
AR109494A1 (es) 2018-12-12
JP2019531341A (ja) 2019-10-31
LT3506886T (lt) 2024-09-10
JP2021105033A (ja) 2021-07-26
JOP20170170A1 (ar) 2019-01-30
KR102444154B1 (ko) 2022-09-16
CA3035252A1 (en) 2018-03-08
SMT202400333T1 (it) 2024-09-16
MX2019002338A (es) 2019-08-16
MA46109A (fr) 2019-07-10
KR20210135618A (ko) 2021-11-15
PY1763675A (es) 2019-01-01
JOP20170170B1 (ar) 2022-09-15
NZ751988A (en) 2021-09-24
PH12019500365A1 (en) 2019-11-04
JP6864747B2 (ja) 2021-04-28
PE20190469A1 (es) 2019-04-04
SG10202100697PA (en) 2021-02-25
UY37391A (es) 2018-02-28
EP3506886A1 (en) 2019-07-10
PL3506886T3 (pl) 2024-12-16
TWI719245B (zh) 2021-02-21
CL2019000508A1 (es) 2019-06-28
UA122733C2 (uk) 2020-12-28
CN116327917A (zh) 2023-06-27
BR112019003479A2 (pt) 2019-05-21
AU2017321605B2 (en) 2020-10-08
FI3506886T3 (fi) 2024-08-20
HUE068084T2 (hu) 2024-12-28
PT3506886T (pt) 2024-08-21

Similar Documents

Publication Publication Date Title
ECSP19021312A (es) Formulaciones de anticuerpos inhibidores de masp-2 altamente concentrados, de baja viscosidad, kits, y métodos
ECSP19015192A (es) Composiciones y métodos de inhibir masp-3 para el tratamiento de diversas enfermedades y trastornos
DOP2019000180A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
CL2018003597A1 (es) Pirimidin-2-ilamino-1h-pirazoles como inhibidores delrrk2 para el uso en el tratamiento de trastornos neurodegenerativos.
CL2018003142A1 (es) Moduladores de la vía de estrés integrada
CL2018001899A1 (es) Salicilamidas de espiroheptanos y compuestos relacionados como inhibidores de cinasa rho (rock)
CL2018000687A1 (es) Nuevos compuestos bicíclicos como inhibidores de atx.
MX2018008052A (es) Inhibidores de desmetilasa especifica de lisina 1 (lsd1).
BR112018067408A2 (pt) formas sólidas de um inibidor de acc de tienopirimidinadiona e métodos para a produção das mesmas
ECSP17023281A (es) Inhibidores de mk2 y sus usos
MX381046B (es) Anticuerpos anti-csf1r e inhibidores de pd-1/pd-l1, y usos de los mismos para el tratamiento de cáncer remisión a las solicitudes relacionadas.
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
MX2017016655A (es) Formulaciones oftalmicas de inhibidores de tirosina quinasa, metodos de uso de las mismas y metodos de preparacion de las mismas.
CR20170219A (es) Inhibidores del bromodominio
MX2022000053A (es) Moduladores de interaccion de sestrina-gator2 y sus usos.
GT201600250A (es) Compuestos de 1, 3, 4- tiadiazol y uso de los mismos para el tratamiento del cáncer
CL2017000715A1 (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo
BR112017027721A2 (pt) formulação de alta concentração
MX2018007390A (es) Composiciones que comprenden acido 15-hidroxi eicosapentaenoico (15-hepe) y metodos de uso del mismo.
ECSP18018793A (es) Compuestos útiles para inhibir ror-gamma-t
CL2020000397A1 (es) Formulaciones de anticuerpos inhibitorio para masp-2 de baja viscosidad altamente concentradas, kits, y métodos de tratamiento de sujetos que sufren de síndrome hemolítico atípico.
MX2021011334A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
MX2021003888A (es) Nuevos compuestos utiles para el tratamiento de enfermedades cardiovasculares.
SV2017005474A (es) Nuevas formas sólidas de desvenlafaxina
CL2016002842A1 (es) Sales mesilato de s- y r-pirlindol composición farmacéutica que las comprende útiles para el tratamiento de la depresión.